HealthCare Global Enterprises and Accenture Partner to Revolutionize Cancer Research with AI

HCG, Accenture Partner to Transform Cancer Research with AI

This partnership will leverage Accenture's generative AI studios to drive innovation in drug discovery, biomarker identification, and treatment pathway development. HealthCare Global Enterprises Limited (HCG), India's largest cancer care network, has partnered with Accenture to transform cancer research and treatment using generative AI and deep learning. This strategic collaboration aims to accelerate precision medicine development in South Asia by analysing multi-dimensional and multi-omic patient data to enable earlier detection and more effective treatments for various cancers. The initiative combines HCG's clinical oncology expertise with Accenture's global capabilities in AI, machine learning, and quantum computing to uncover molecular alterations with significant implications for patient care. The partnership, a first in South Asia, will leverage Accenture's generative AI studios to drive innovation in drug discovery, biomarker identification, and treatment pathway development. Today, optimising cancer care necessarily calls for tech-driven advancements in research and academics, especially for ensuring seamless, error-free data collection and streaming. Given the heterogenicity of tumor genomics and other forms of omics, AI has become integral to precise, personalised medical advancements. Highlighting the initiative's significance, Dr. B.S. Ajaikumar, executive chairman of HCG, said cancer care today is necessitated by technological advancement, and collaborations can enhance the research and service offerings. "Accenture's deep expertise in technology and analytics, leveraging AI modeling, will help us enhance our research aimed at developing patient-centric therapies with lasting outcomes," he said. Advanced technologies such as image analysis software, informatics, and novel algorithms are used to study cancer data and create new insights into cancer biology. Initial efforts focus on identifying molecular signatures for lung adenocarcinoma and head and neck cancers, which will later extend to other cancer types. The program also seeks to enhance understanding of cancer development, origins, and symptoms, advance treatment algorithms for precision medicine, and improve therapy outcomes. Senthil Ramani, global lead of data and AI at Accenture, remarked that next-gen computing, including generative AI, combined with deep biological and clinical expertise, can play a pivotal role in cancer research. "Together with HCG, we are blending our global expertise in data and AI along with life sciences R&D to rapidly and accurately improve decision-making for the treatment and care for cancer patients in South Asia, and across the world," Ramani said. AI has been making significant strides in healthcare, and big tech companies are investing heavily in the sector. NVIDIA, Microsoft and Google, have all been focusing on leveraging generative AI for functions such as report reading, summarisation, drug discovery and many other activities.

HealthCare Global Enterprises Limited and Accenture Collaborate on Cancer Research and Care Using Advanced AI

Innovative, data-driven program to accelerate cancer research in South Asia HealthCare Global Enterprises Limited (HCG), one of the largest cancer care networks in India, is collaborating with Accenture (NYSE: ACN) to accelerate cancer research and care through the use of advanced AI, including generative AI and deep learning on multi-dimensional and multi-omic patient data. This strategic teaming combines Accenture's global expertise and talent in data and AI including AI/ML, generative AI, and quantum computing with deep clinical insights from HCG in oncology to enable early detection and treatment for various types of cancer. As part of the joint effort, Accenture will use advanced technologies including image analysis software, informatics, and novel algorithms to analyze data from cancer patients and study molecular alterations that can have a broader impact on patient care. The program, the first of its kind in South Asia, will leverage Accenture's generative AI studios to spur innovative research for the discovery and development of new drug targets, mechanisms and pathways, and biomarkers associated with different forms of cancer. Additionally, the initiative aims to enhance the understanding of various cancers, including their development, symptoms, and origins, to enable new treatment algorithms for precision medicine and advance the quality of therapy and care. It will showcase data-driven clinical practice and enhance the overall efficiency of patient care by applying AI, generative AI, cloud, machine learning, and quantum computing, among others. The collaboration is currently focused on identifying molecular signatures for the prognosis and response to therapy for lung adenocarcinoma, and head and neck cancers, which will then be extended to other cancer types. Dr. B. S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Limited, said, "Today, optimizing cancer care necessarily calls for tech-driven advancements in research and academics, especially for ensuring seamless, error-free data collection and streaming. Given the heterogenicity of tumor genomics and other forms of omics, AI has become integral to precise, personalized medical advancements. AI-powered innovation has activated established drugs in certain tumors, which was not the case previously. Accenture's deep expertise in technology and analytics, leveraging AI modeling, will help us enhance our research aimed at developing patient-centric therapies with lasting outcomes. This collaborative initiative, an integral part of our in-house research endeavors, is a fitting testament to our stature as a cancer care leader focused on disruptive innovation." Senthil Ramani, Global Lead of Data and AI at Accenture, said, "Next-gen computing, including generative AI, combined with deep biological and clinical expertise, can play a pivotal role in cancer research and care, addressing needs of patients and benefiting the global healthcare industry at large. Together with HCG, we are blending our global expertise in data and AI along with life sciences R&D to rapidly and accurately improve decision-making for the treatment and care for cancer patients in South Asia, and across the world." About HealthCare Global Enterprises Ltd. HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 22 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under the "Milann" brand, HCG operates 7 fertility centers. https://www.hcgoncology.com/ About Accenture Accenture is a leading global professional services company that helps the world's leading organizations build their digital core, optimize their operations, accelerate revenue growth and enhance services -- creating tangible value at speed and scale. We are a talent- and innovation-led company with 774,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world's leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at accenture.com.